EGFR and non-small cell lung carcinoma: This is especially the case for c.2369C>T p.(Thr790Met), as this variant has been reported to occur in less than 5% of treatment naïve primary lung cancers, but in 50% of treated NSCLC as a concomitant resistance variant in combination with another sensitizing EGFR variant [15].